Thyroid Surgery — Procedure Guide, Recovery & Risks | MyMedicPlus

Thyroid surgery removes part (hemithyroidectomy or thyroid lobectomy) or all (total thyroidectomy) of the thyroid gland via a transverse Kocher collar incision at the base of the neck. The thyroid is the butterfly-shaped endocrine gland responsible for producing thyroxine (T4) and triiodothyronine (T3), which regulate metabolism, heart rate, and body temperature. Minimally invasive video-assisted (MIVAT) and robotic remote-access approaches (transaxillary, retroauricular) avoid a visible neck scar in selected patients. Total thyroidectomy requires lifelong levothyroxine hormone replacement therapy. The procedure is performed by specialist endocrine or head-and-neck surgeons at high-volume centres.

The extent of surgery depends on the indication: hemithyroidectomy (removal of one lobe) is appropriate for unifocal low-risk papillary thyroid cancer under 4 cm with no high-risk features, and for indeterminate thyroid nodules (Bethesda IV/V cytology) requiring excision for histological diagnosis. Total thyroidectomy is performed for larger, bilateral, or high-risk thyroid cancer, Graves' disease requiring surgery, and large compressive goitre. The procedure may be performed via open Kocher incision (gold standard), endoscopic transaxillary, or robotic-assisted approaches at specialist centres to avoid neck scarring. The Kocher collar incision heals to a virtually imperceptible scar in most patients over 12–18 months, particularly in younger patients with good skin healing.

Indications include papillary, follicular, medullary, and anaplastic thyroid cancer; toxic multinodular goitre not responding to radioiodine or antithyroid medications; Graves' disease refractory to medical therapy; compressive symptoms (dysphagia, dyspnoea, stridor) from large goitres; cosmetically disfiguring goitre; and indeterminate thyroid nodules on fine-needle aspiration cytology (Bethesda III-V categories). Pre-operative risk assessment includes laryngoscopy to document vocal cord movement, calcium and PTH levels, thyroid function tests, and high-resolution ultrasound to characterise nodules and assess lymph node involvement before surgery.

Thyroid nodule management follows the ATA (American Thyroid Association) or British Thyroid Association guidelines: nodules greater than 1 cm with suspicious ultrasound features (irregular margins, microcalcifications, hypoechogenicity, taller-than-wide shape) are biopsied by ultrasound-guided fine needle aspiration cytology (FNAC). Bethesda I–II cytology is benign; III–IV is indeterminate (surgical excision for diagnosis); V–VI is malignant/highly suspicious (total thyroidectomy). Central neck dissection (level VI lymph node clearance) is added for cytologically confirmed thyroid cancer with N1 nodal disease on pre-operative imaging.

Under general anaesthesia with continuous intraoperative recurrent laryngeal nerve (RLN) monitoring, a 4-6 cm transverse neck incision is made 2 cm above the sternal notch. Subplatysmal flaps are raised and strap muscles retracted. The thyroid lobe is mobilised by dividing the middle thyroid vein and superior pole vessels; superior and inferior thyroid arteries are ligated close to the thyroid capsule to protect parathyroid blood supply. The RLN and four parathyroid glands are identified and meticulously preserved under magnification. The isthmus is divided for hemithyroidectomy or both lobes are removed for total thyroidectomy. The wound is closed in layers with absorbable sutures or skin glue. A surgical drain may be placed at the surgeon's discretion.

Intraoperative parathyroid identification is critical — parathyroid glands are identified by their characteristic tawny-yellow colour and pedicle vascularity and preserved in situ on their vascular pedicle whenever possible. If devascularised, parathyroid tissue is immediately auto-transplanted in fragments into the sternocleidomastoid muscle to restore function. Near-infrared fluorescence imaging using indocyanine green (ICG) assesses parathyroid viability intraoperatively and is increasingly used at specialist centres to reduce hypoparathyroidism rates. Near-infrared fluorescence imaging using indocyanine green (ICG) is increasingly used to assess parathyroid viability and guide preservation decisions intraoperatively. Bipolar diathermy or ultrasonic energy devices (Harmonic Focus, LigaSure) provide haemostasis during dissection. The superior thyroid vessels are individually ligated close to the thyroid to protect the external branch of the superior laryngeal nerve.

The 10-year disease-specific survival for papillary thyroid cancer after total thyroidectomy and radioiodine is over 95% for Stage I-III disease. Hemithyroidectomy is oncologically adequate for low-risk papillary microcarcinoma below 1 cm with no extrathyroidal extension. Symptomatic goitre relief is achieved in over 95% of patients; symptom recurrence from remnant regrowth is under 5%. Graves' disease is cured by total thyroidectomy in essentially 100% of cases within days. In experienced high-volume centres (over 25 thyroidectomies per year), permanent complication rates are significantly lower than low-volume surgeons.

Minimally invasive approaches (transaxillary robotic, oral vestibular endoscopic) avoid visible neck scarring entirely — a significant benefit for young patients concerned about cosmesis. Molecular testing of indeterminate thyroid nodules (Afirma gene expression classifier, ThyroSeq v3) may reclassify Bethesda III/IV nodules as benign (negative predictive value 91–95%), potentially avoiding diagnostic hemithyroidectomy in nearly half of such cases. Post-operative radioiodine (I-131) ablation after total thyroidectomy for intermediate- and high-risk thyroid cancer reduces local recurrence rates and enables thyroglobulin as a cancer marker for surveillance.

Temporary vocal cord paresis from RLN traction occurs in 3-5%; permanent RLN palsy is below 1% in experienced centres performing continuous nerve monitoring. Temporary hypocalcaemia from parathyroid bruising occurs in 10-20% after total thyroidectomy; permanent hypoparathyroidism occurs in below 2% at specialist centres. Wound haematoma (1-2%) may require emergency re-exploration if expanding and causing airway compromise. Post-operative hypothyroidism after total thyroidectomy is universal, requiring lifelong levothyroxine. Radioiodine ablation may follow for intermediate- or high-risk thyroid cancers.

Hypoparathyroidism is the most common long-term complication of total thyroidectomy, resulting from inadvertent removal or devascularisation of all four parathyroid glands. Acute hypocalcaemia (tetany, perioral tingling, Chvostek's sign) occurs in 20–30% transiently and requires oral or IV calcium supplementation. Permanent hypoparathyroidism occurs in 1–3% at specialist centres and requires lifelong calcium and activated vitamin D (alfacalcidol or calcitriol) supplementation, with monitoring to avoid hypercalciuria and nephrocalcinosis. Superior laryngeal nerve (SLN) external branch injury causes weakness of the cricothyroid muscle, resulting in loss of high-pitched voice projection — relevant for singers and voice professionals.

Most patients are discharged within 24 hours. A small drain, if placed, is removed before discharge. Serum calcium is checked at 6 hours post-operatively; calcium and active vitamin D are prescribed after total thyroidectomy as a precaution. Levothyroxine replacement begins the day after total thyroidectomy. Sutures or clips are removed at 7-10 days. Patients return to light desk work within 1-2 weeks and full activity in 2-3 weeks. Scar healing is optimised with silicone gel sheets and SPF30+ sunscreen from 6 weeks. Thyroid cancer patients undergo radioiodine therapy at 4-6 weeks when hypothyroid or following rhTSH stimulation.

After total thyroidectomy for thyroid cancer, patients require lifelong levothyroxine at a TSH-suppressive dose (TSH 0.1–0.5 mU/L for intermediate risk; TSH less than 0.1 for high risk) to reduce recurrence risk through suppression of TSH-stimulated tumour growth. After hemithyroidectomy, 15–20% of patients develop clinical hypothyroidism requiring levothyroxine. Serum thyroglobulin levels with anti-thyroglobulin antibodies are measured at 3–6 monthly intervals as a tumour marker for recurrence surveillance. Neck ultrasound is performed annually for 5 years in intermediate-risk cases and beyond in high-risk cases.